Results 201 to 210 of about 1,571,981 (263)
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
H-Wave® Device Stimulation for Chronic Knee Pain Disorders: A Patient-Reported Outcome Measures Observational Study. [PDF]
Gupta A, Han D, Norwood SM.
europepmc +1 more source
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Patient-reported Outcome Measures in Head and Neck Reconstruction: A Systematic Review Across Disciplines and Geographical Locations. [PDF]
Pfister P +11 more
europepmc +1 more source
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Patient-Reported Outcome Measures in the Elderly: Do These Reflect Healing Post-Fragility Fracture of the Pelvis? [PDF]
Bartman SE, Whyne C, Stephen D, Nam D.
europepmc +1 more source
Tumor mutational burden as a determinant of metastatic dissemination patterns
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal +4 more
wiley +1 more source
Comparison of the Catquest-9SF and Cat-PROM5 Patient-Reported Outcome Measures: A Literature Review. [PDF]
Britt JM, Ellyson AC.
europepmc +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Bridging the Gap: Do Patient-Reported Outcome Measures Reflect Objective Knee Function After Cartilage Repair? [PDF]
Heinz T +7 more
europepmc +1 more source

